MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO® Plus (fluralaner plus moxidectin) S...
March 21 2018 - 2:00AM
Business Wire
Extended Duration Protection Offers Cats
Enhanced Systemic Nose-to-Toe Parasite Protection
MSD Animal Health (known as Merck Animal Health in the United
States and Canada) today announced that the Committee for Medicinal
Products for Veterinary Use (CVMP) of the European Medicines Agency
has adopted a positive opinion recommending marketing authorization
for the veterinary medicinal product BRAVECTO® Plus (fluralaner
plus moxidectin) spot-on solution for cats.
If granted marketing approval, BRAVECTO® Plus will be a
sustained, broad-spectrum combination topical solution for cats
with, or at risk from, both internal and external parasite
infestations: ticks and fleas, heartworm, roundworm and hookworm.
Detailed conditions of the product will be described in the summary
of product characteristics (SPC), which will be published in the
European public assessment report (EPAR) after marketing
authorization has been granted by the European Commission.
BRAVECTO® Plus is designed for cats with, or at risk from, mixed
parasitic infestations and is applied topically using the unique
“Twist’n’Use”™ pipette design for ease of application.
Once applied, BRAVECTO® Plus provides immediate and persistent
tick (Ixodes ricinus) and flea (Ctenocephalides felis) killing
activity for 12 weeks, prevents heartworm disease caused by
Dirofilaria immitis for 8 weeks, and also treats roundworm and
hookworm.
Ticks and fleas must attach to the treated animal and commence
feeding in order to be exposed to the active substance. BRAVECTO®
Plus also can be used as part of a treatment strategy for flea
allergy dermatitis (FAD).
In 2014, BRAVECTO® was launched as a chewable tablet for dogs
and, in 2016, BRAVECTO® spot-on was launched as a topical solution
for dogs and cats. More than 60 million doses of BRAVECTO® have
been distributed in 72 countries since its introduction.
About MSD Animal Health
For more than a century, MSD, a leading global biopharmaceutical
company, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases. MSD
Animal Health, known as Merck Animal Health in the United States
and Canada, is the global animal health business unit of MSD.
Through its commitment to the Science of Healthier Animals™, MSD
Animal Health offers veterinarians, farmers, pet owners and
governments one of the widest range of veterinary pharmaceuticals,
vaccines and health management solutions and services. MSD Animal
Health is dedicated to preserving and improving the health,
well-being and performance of animals. It invests extensively in
dynamic and comprehensive R&D resources and a modern, global
supply chain. MSD Animal Health is present in more than 50
countries, while its products are available in some 150 markets.
For more information, visit www.msd-animal-health.com or connect
with us on LinkedIn and Twitter.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
There can be no guarantees with respect to pipeline products that
the products will receive the necessary regulatory approvals or
that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2017
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180320006202/en/
Media:Gail S. Thornton, + 1
973-937-5453Gail.Thornton@merck.comorMarco Gassen, +49 89 456
14202Marco.gassen@msd.deorPam Eisele, +1
267-305-3558Pamela.Eisele@merck.comorInvestors:Michael DeCarbo, + 1
908-740-1807Michael.decarbo@merck.com
Merck (NYSE:MRK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2023 to Sep 2024